AbbVie's Spin-Out Culture Helped Set Post-Humira Strategy, Execs Say
Addressing an investor meeting, CFO Bill Chase said Humira should continue strong growth through 2022, while helping leverage the launch and ramp up of successors like risankizumab and upadacitinib.
You may also be interested in...
Fourth Act For AbbVie's Risankizumab Whets Appetite
AbbVie has released more positive top-line data for its anti-IL23 product risankizumab, building a strong case for its use in psoriasis – but there is still more to come from the study amid uncertainty over how the product will deal with competitive and pricing pressure.
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.
Is Triple Phase III Triumph for AbbVie's Risankizumab In Psoriasis Good Enough?
AbbVie's investigational monoclonal antibody therapy risankizumab has triumphed against its competitors in three Phase III trials in psoriasis, but will it be too late to the party to enjoy the full commercial benefits?